Publications by authors named "Dennis Teng"
Article Synopsis
- Risankizumab, an anti-interleukin-23 antibody, is being studied as a treatment for moderate-to-severe Crohn's disease, focusing specifically on Asian patients.
- The study involved two major clinical trials that tested the drug's performance against a placebo in patients who had not responded to other treatments, with follow-up maintenance therapy for those who showed improvement.
- Results indicated that risankizumab led to significant clinical remission and endoscopic response rates, with a safety profile comparable to that of non-Asian populations, reinforcing its potential effectiveness for Asian patients with Crohn's disease.
Article Synopsis
- Researchers studied the effects of adalimumab treatment on metabolite and lipid profiles in fecal samples from ulcerative colitis (UC) patients and healthy controls, aiming to predict clinical remission outcomes.
- They found significant differences in fecal metabolites between UC patients and healthy individuals, with remitters displaying metabolite levels more similar to healthy controls after treatment, whereas lipid profiles were less indicative of treatment outcomes.
- The study developed a prediction model for long-term remission in male UC patients based on lipid biomarkers, outperforming traditional clinical markers.
Background/aims: Epidemiological data on steroid use in South Korean patients with inflammatory bowel disease (IBD) are limited. We documented the steroid use patterns in these patients, and whether physician education on appropriate steroid use affected these patterns.
Methods: ACTION was an observational cohort study conducted in adults (≥19 years) with IBD.
Article Synopsis
- A study was conducted to evaluate the effectiveness and safety of the drug adalimumab (ADA) in treating Korean patients with ulcerative colitis (UC) over 56 weeks.
- The results showed that at 8 and 56 weeks, clinical response rates were 52.1% and 37.7%, with remission rates at 24.0% and 22.0%, indicating moderate success in treatment.
- Higher ADA drug levels were linked to better outcomes, and certain patient characteristics, like lower disease activity and higher body mass index, predicted better response rates, while serious side effects were rare, occurring in only 2.8% of patients.